JERUSALEM, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera” or the "Company”), a leader in the ...

RV camping is always fun, but it can quickly be ruined if you make an etiquette misstep. Here's what to know before you head ...

ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for ...

Q3 2025 Earnings Call Transcript November 13, 2025Protalix BioTherapeutics, Inc. misses on earnings expectations.

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter ...

Q3 2025 Earnings Call November 12, 2025 5:00 PM ESTCompany ParticipantsRenata Couto - Investor Relations Executive ManagerVirgilio ...

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX) a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today reported ...

Operator: Ladies and gentlemen, thank you for joining us today. And third quarter 2025 results conference call. At this time, ...

Travelers and Chubb trade at low valuations with strong fundamentals and low market correlation, offering hidden value. Read ...

New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates ...

Things that seem completely normal for rich people can be completely disconnected from the reality of the average person.

Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML Remains on track to initiate Phase 3 pivotal trial of ELVN-001 ...